uniQure NV (QURE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 52/100 (HIGH), 7.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 16.23% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next
- uniQure Plunges on Additional Data From Huntington's Disease Study
- uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far
- QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
- uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit
- Why Is uniQure Stock Sinking on Tuesday?
- UniQure Insists Huntington’s Drug Is Still on Track as Stock Plunges 36%
- uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. — Brain 2024 Aug 1 PMID 39074992
- Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. — Nat Med 2024 Feb PMID 38182785
- Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. — J Thromb Haemost 2021 Jun PMID 33587824
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for uniQure NV.
Full QURE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.